We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App

Whole-Body PET/CT Predicts Response to HER2-Targeted Therapy in Metastatic Breast Cancer Patients

By MedImaging International staff writers
Posted on 28 Sep 2023
Print article
Image: Imaging entire body instead of only the primary cancer site can provide a total estimate of HER2 expression (Photo courtesy of 123RF)
Image: Imaging entire body instead of only the primary cancer site can provide a total estimate of HER2 expression (Photo courtesy of 123RF)

Around 20% of women diagnosed with breast cancer show overexpression of human epidermal growth factor receptor 2 (HER2), making it a key therapy target for new as well as recurring cases. Yet, treatments that target HER2 often fail because breast cancer is not a one-size-fits-all disease; even within the same patient, HER2 levels can change. Now, new research indicates that a novel imaging agent, 68Ga-ABY-025, may help address this challenge by predicting early metabolic responses to HER2-specific therapies in patients with HER2-positive metastatic breast cancer. This agent, when used with PET/CT scans, can offer whole-body quantification of HER2 levels, aiding in treatment planning and potentially sparing patients from the unnecessary side effects of drugs.

Researchers at Uppsala University (Uppsala, Sweden) investigated the use of 68Ga-ABY-025 PET as a non-invasive method for whole-body HER2-receptor quantification. The study involved 40 patients confirmed to have HER2-positive status—19 with primary breast cancer and 21 with metastatic forms of the disease (with an average of three prior treatments). For each patient, baseline evaluations were carried out using 68Ga-ABY-025 PET/CT, alongside another type of PET/CT scan known as 18F-FDG and core-needle biopsies from selected lesions. Following two rounds of therapy, 18F-FDG PET/CT scans were conducted once again to examine changes in the way the tumor lesions metabolize sugar.

The scientists recorded tracer uptake in up to five of the largest lesions in each patient, including those from which biopsies were taken. They then compared these standardized uptake values from the 68Ga-ABY-025 PET/CT scans with biopsy-confirmed HER2 status and observed changes in tumor metabolism. The study revealed that 68Ga-ABY-025 PET/CT effectively quantified HER2 levels, and this uptake had a significant correlation with the metabolic response in patients, notably in those dealing with metastatic breast cancer. Moreover, the research showed that patients who had undergone more rounds of previous treatments needed higher levels of 68Ga-ABY-025 to trigger a metabolic response.

“The ability of 68Ga-ABY-025 PET/CT to provide a whole-body visualization of HER2 expression and to predict metabolic response is advantageous and exceeded the biopsy-based approach for metastatic breast cancer patients,” said Ali Alhuseinalkhudhur, MD, PhD candidate in the Department of Immunology, Genetics, and Pathology at Uppsala University. “HER2-based imaging tools might provide a solution in situations where biopsies cannot be performed safely or when biopsy results are inconsistent. In addition, a PET-based approach to evaluate the appropriateness of targeted therapy might help avoid unnecessary side effects and might provide a more personalized opportunity for timely therapy corrections.”

Related Links:
Uppsala University

Gold Member
Solid State Kv/Dose Multi-Sensor
Portable Digital X-Ray System
Acuity PDR
Trimline Basic
1.5T MRI Scanner

Print article



view channel
Image: The artificial intelligence model outperformed clinical tests at predicting the progress of Alzheimer’s disease (Photo courtesy of 123RF)

AI Outperforms Clinical Tests at Predicting Alzheimer’s Progress from MRI Scans

Dementia is a major global health challenge, impacting over 55 million individuals worldwide and costing approximately USD 820 billion annually. Projections indicate that the number of cases will nearly... Read more


view channel
Image: The new FDA-cleared AI-enabled applications have been integrated into the EPIQ CVx and Affiniti CVx ultrasound systems (Photo courtesy of Royal Philips)

Next-Gen AI-Enabled Cardiovascular Ultrasound Platform Speeds Up Analysis

Heart failure is a significant global health challenge, affecting approximately 64 million individuals worldwide. It is associated with high mortality rates and poor quality of life, placing a considerable... Read more

General/Advanced Imaging

view channel
Image: The NeuroLF ultra-compact brain Positron Emission Tomography (PET) scanner (Photo courtesy of Positrigo)

Breakthrough Brain PET System Aids Diagnosis of Neurological Disorders

Alzheimer's disease (AD) is the most prevalent type of dementia, representing approximately 70% of all dementia cases in individuals over 60 years of age. As of 2020, there were more than 55 million people... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Calantic Digital Solutions is an orchestrated suite of AI radiology solutions that aims to transform radiology (Photo courtesy of Bayer)

Bayer and Rad AI Collaborate on Expanding Use of Cutting Edge AI Radiology Operational Solutions

Imaging data constitutes approximately 90% of all medical data, with the volume of such data continuously expanding, thereby significantly increasing the workload for radiologists amid existing resource limitations.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.